Format

Send to

Choose Destination
Leuk Res. 2009 Sep;33(9):1255-9. doi: 10.1016/j.leukres.2008.11.024. Epub 2009 Jan 14.

Transfection with mRNA for CD19 specific chimeric antigen receptor restores NK cell mediated killing of CLL cells.

Author information

1
Molecular Oncology Research Institute-Tufts Medical Center, 800 Washington Street-Box 5609, Boston, MA 02111, USA. lboissel@tuftsmedicalcenter.org

Abstract

An emerging treatment option for chronic lymphocytic leukemia (CLL) is to make cytotoxic immune cells express a chimeric antigen receptor (CAR) that recognizes specific surface molecules on CLL cells. Here an mRNA coding for an anti-CD19 CAR was transfected into the NK-92 cell line by electroporation. In contrast to cDNA, mRNA resulted in high transfection efficiency (47.2 +/- 8% versus <5% for cDNA) with minimal effect on cell viability. NK-92 cells expressing anti-CD19 CAR killed previously resistant CD19+ B-ALL cell lines, as well as primary CLL cells and therefore may present a safe, cell-based, targeted treatment for patients with CLL.

PMID:
19147228
PMCID:
PMC3047414
DOI:
10.1016/j.leukres.2008.11.024
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center